Introduction {#sec1}
============

Ovarian cancer is the fifth most lethal malignancy amongst women diagnosed with cancers in the United States with approximately 14240 cancer-related deaths from this disease annually \[[@B1]\]. Combination of surgery and chemotherapy is the standard treatment for the advanced stage in ovarian cancer \[[@B2]\]. Despite considerable efforts to improve early detection and advances in chemotherapy, the 5-year survival rate remains only 30% \[[@B3]\]. Identification of favorable prognostic biomarkers for ovarian cancer, in some ways, could improve clinical outcomes of these patients.

Signal transducer and activator of transcription (STAT), a family of latent cytoplasmic transcription factors, is composed of seven identified members (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6) \[[@B4]\]. These genes are activated in response to cytokines, hormones, and growth factors \[[@B4]\]. Ligand-dependent activation of STATs, which is a transient process lasting from minutes to hours, plays important roles in regulating cell proliferation, cellular transformation, tumor formation, and immune responses and is also involved in tumorigenesis, metastasis, and angiogenesis \[[@B4]\]. Indeed, previous studies have shown that STATs were constitutively activated in ovarian cancer and played a pivotal role in oncogenesis of this disease \[[@B8],[@B9]\].

Since STAT family plays an important role in the initiation and development of cancers, these genes have been well studied as a prognostic predictor for a considerable number of solid tumors \[[@B10]\]. However, the prognostic value of the STAT family in ovarian cancer patients is limited and the results remain controversial \[[@B23]\]. In the present study, we first comprehensively explored the prognostic significance of seven *STAT* genes in patients with ovarian carcinoma by using the Kaplan--Meier plotter (KM plotter).

Materials and methods {#sec2}
=====================

KM plotter database {#sec2-1}
-------------------

An online database (<http://kmplot.com/analysis/>) \[[@B27]\] was used to investigate the association between individual*STAT* mRNA levels and overall survival (OS) of ovarian cancer patients. Currently, this database is capable of assessing the effect of 54675 genes of survival in breast cancer \[[@B27]\], ovarian cancer \[[@B28]\], lung cancer \[[@B29]\], as well as gastric cancer data. In this database, gene expression data and OS information of 1582 ovarian cancer patients were downloaded from Gene Expression Omnibus, Cancer Biomedical Informatics Grid, and The Cancer Genome Atlas cancer datasets \[[@B29]\]. Additionally, they offered clinical data, such as histology, grade, stage, TP53 mutation status, and treatment of ovarian cancer patients.

In simpler terms, seven *STAT* members (*STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b*, and *STAT6*) were entered into the database (<http://kmplot.com/analysis/index.php?p=service&cancer=ovar>) to get Kaplan--Meier survival plots. The expression cut-off points of individual *STAT* genes were determind according to their median mRNA levels amongst the selected ovarian cancer samples. *STAT* expression status were finally classified into 'low' and 'high' according to the comparisons between expression values with established cutoffs. The two patient cohorts were compared with a Kaplan--Meier survival plot, and then hazard ratio (HR), 95% confidence intervals (CIs), and log-rank *P* were determined and presented on internet.

Results {#sec3}
=======

In our present study, all the seven *STAT* members' Kaplan--Meier survival information can be determined on [www.kmplot.com](http://www.kmplot.com). We initially evaluated the prognostic value of *STAT1* in the database. Affymetrix IDs for *STAT1*: 200887_s\_at. OS curves were plotted for all the ovarian cancer patients (*n*=1582) ([Figure 1](#F1){ref-type="fig"}A), for serous cancer patients (*n*=1138) ([Figure 1](#F1){ref-type="fig"}B), and for endometrioid cancer patients (*n*=36) ([Figure 1](#F1){ref-type="fig"}C). High mRNA expression of *STAT1* was related to a better OS in all the ovarian cancer patients, HR =0.84 (0.71−0.98), *P*=0.025, especially for serous ovarian cancer patients, HR =0.81 (0.68−0.95), *P*=0.0093, but not in endometrioid cancer patients, HR =300485201.86 (0−Inf), *P*=0.17.

![The prognostic value of *STAT1* expression in ovarian cancer.\
The prognostic value of *STAT1* expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for *STAT1*: 200887_s\_at. OS curves are plotted for (**A**) all the patients (*n*=1582), (**B**) serous cancer patients (*n*=1138), and (**C**) endometrioid cancer patients (*n*=36).](bsr-37-bsr20170650-g1){#F1}

We then evaluated the prognostic significance of *STAT2* mRNA expression in the database. Affymetrix IDs for *STAT2*: 225636_at. *STAT2* mRNA level showed a null association with OS amongst all the ovarian cancer patients, HR =1.00 (0.80−1.26), *P*=0.97 ([Figure 2](#F2){ref-type="fig"}A), serous ovarian cancer patients, HR =1.04 (0.81−1.34), *P*=0.74 ([Figure 2](#F2){ref-type="fig"}B), as well as endometrioid ovarian cancer patients, HR =2.92 (0.30−28.15), *P*=0.33 ([Figure 2](#F2){ref-type="fig"}C).

![The prognostic value of *STAT2* expression in ovarian cancer.\
The prognostic value of *STAT2* expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for *STAT2*: 225636_at. OS curves are plotted for (**A**) all the patients (*n*=580), (**B**) serous cancer patients (*n*=453), and (**C**) endometrioid cancer patients (*n*=29).](bsr-37-bsr20170650-g2){#F2}

[Figure 3](#F3){ref-type="fig"} showed the prognostic value of *STAT3* in the database. Affymetrix IDs for *STAT3*: 225289_at. Increased *STAT3* mRNA expression had no effect on OS for all ovarian cancer patients, HR =0.85 (0.68--1.06), *P*=0.14 ([Figure 3](#F3){ref-type="fig"}A), as well as serous cancer patients, HR =0.85 (0.66--1.09), *P*=0.2 ([Figure 3](#F3){ref-type="fig"}B). However, *STAT3* mRNA expression predicted a better OS in 29 endometrioid cancer patients, HR =0 (0−Inf), *P*=0.025 ([Figure 3](#F3){ref-type="fig"}C).

![The prognostic value of *STAT3* expression in ovarian cancer.\
The prognostic value of *STAT3* expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for *STAT3*: 225289_at. OS curves are plotted for (**A**) all the patients (*n*=580), (**B**) serous cancer patients (*n*=453), and (**C**) endometrioid cancer patients (*n*=29).](bsr-37-bsr20170650-g3){#F3}

[Figure 4](#F4){ref-type="fig"} showed the prognostic value of *STAT4* in the database. Affymetrix IDs for *STAT4*: 206118_at. Overexpression of *STAT4* mRNA was significantly related to a favorable OS for all the ovarian cancer patients, HR =0.81 (0.70−0.92), *P*=0.0015 ([Figure 4](#F4){ref-type="fig"}A), serous cancer patients, HR =0.78 (0.65−0.93), *P*=0.0054 ([Figure 4](#F4){ref-type="fig"}B). However, *STAT4* mRNA expression was uncorrelated with OS in endometrioid cancer patients, HR =2.33 (0.39−13.97), *P*=0.34 ([Figure 4](#F4){ref-type="fig"}C).

![The prognostic value of *STAT4* expression in ovarian cancer.\
The prognostic value of *STAT4* expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for *STAT4*: 206118_at. OS curves are plotted for (**A**) all the patients (*n*=1582), (**B**) serous cancer patients (*n*=1138), and (**C**) endometrioid cancer patients (*n*=36).](bsr-37-bsr20170650-g4){#F4}

[Figures 5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"} presented the prognostic significance of *STAT5a* and *STAT5b*, respectively. Affymetrix IDs were as following: 203010_at (*STAT5a*) and 212549_at (*STAT5b*). Both elevated *STAT5a* and *STAT5b* mRNA expression are associated with a favorable OS for all the ovarian cancer patients (*STAT5a*: *P*=0.036, [Figure 5](#F5){ref-type="fig"}A; *STAT5b*: *P*=0.028, [Figure 6](#F6){ref-type="fig"}A). Nevertheless, with regard to serous ovarian cancer patients and endometrioid ovarian cancer patients, there was no significant difference in HR estimates between study strata ([Figure 5](#F5){ref-type="fig"} B,5C and [Figure 6](#F6){ref-type="fig"}B,6C).

![The prognostic value of *STAT5a* expression in ovarian cancer.\
The prognostic value of *STAT5a* expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for *STAT5a*: 203010_at. OS curves are plotted for (**A**) all the patients (*n*=1582), (**B**) serous cancer patients (*n*=1138), and (**C**) endometrioid cancer patients (*n*=36).](bsr-37-bsr20170650-g5){#F5}

![The prognostic value of *STAT5b* expression in ovarian cancer.\
The prognostic value of *STAT5b* expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for *STAT5b*: 212549_at. OS curves are plotted for (**A**) all the patients (*n*=1582), (**B**) serous cancer patients (*n*=1138), and (**C**) endometrioid cancer patients (*n*=36).](bsr-37-bsr20170650-g6){#F6}

Finally, we investigated the prognostic significance of *STAT6* mRNA expression in the database. Affymetrix IDs for *STAT6*: 201331_s\_at. High levels of *STAT6* mRNA were significantly correlated to a favorable OS for all the ovarian cancer patients, HR =0.79 (0.69−0.9), *P*=0.00062 ([Figure 7](#F7){ref-type="fig"}A). Nevertheless, *STAT6* showed no effect on OS either amongst serous cancer patients, HR =0.87 (0.74−1.02), *P*=0.082 ([Figure 7](#F7){ref-type="fig"}B) or endometrioid cancer patients, HR =3.57 (0.6−21.37), *P*=0.14([Figure 7](#F7){ref-type="fig"}C).

![The prognostic value of *STAT6* expression in ovarian cancer.\
The prognostic value of *STAT6* expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for *STAT6*: 201331_s\_at. OS curves are plotted for (**A**) all the patients (*n*=1582), (**B**) serous cancer patients (*n*=1138), and (**C**) endometrioid cancer patients (*n*=36).](bsr-37-bsr20170650-g7){#F7}

To further explore the correlation of individual *STAT* with other clinicopathological features, we investigated the correlation with pathological grades ([Table 1](#T1){ref-type="table"}), clinical stages ([Table 2](#T2){ref-type="table"}), TP53 mutation ([Table 3](#T3){ref-type="table"}) of ovarian cancer patients. As shown in [Table 1](#T1){ref-type="table"}, high expression of *STAT1, STAT3, STAT4*, and *STAT6* mRNA were correlated to a better OS in grade III ovarian cancer patients, but not in grade I or II ovarian cancer patients ([Table 1](#T1){ref-type="table"}).

###### Correlation of *STAT* gene expression level with OS in different pathological grades in ovarian cancer patients

  STAT     Pathological grade   Cases   HR (95% CI)         *P*-value
  -------- -------------------- ------- ------------------- -------------------------------------------
  STAT1    I                    56      2.19 (0.84−5.76)    0.1
           II                   315     1.32 (0.95−1.83)    0.1
           III                  968     0.73 (0.61−0.87)    0.00039[\*](#T1TFN1){ref-type="table-fn"}
  STAT2    I                    41      1.91 (0.59−6.16)    0.27
           II                   153     1.33 (0.83−2.14)    0.24
           III                  344     1 (0.76−1.31)       0.98
  STAT3    I                    41      0.67 (0.22--2.02)   0.47
           II                   153     1.03 (0.65--1.63)   0.89
           III                  344     0.75 (0.57--0.99)   0.039[\*](#T1TFN1){ref-type="table-fn"}
  STAT4    I                    56      2.23 (0.85−5.89)    0.096
           II                   315     0.76 (0.53−1.07)    0.12
           III                  968     0.73 (0.62−0.87)    0.00044[\*](#T1TFN1){ref-type="table-fn"}
  STAT5a   I                    56      2.05 (0.67−6.25)    0.2
           II                   315     0.79 (0.58−1.08)    0.14
           III                  968     0.88 (0.74−1.04)    0.13
  STAT5b   I                    56      1.66 (0.59−4.7)     0.34
           II                   315     0.81 (0.59−1.1)     0.17
           III                  968     0.84 (0.69−1.03)    0.088
  STAT6    I                    56      6.39 (1.82−22.44)   0.00094[\*](#T1TFN1){ref-type="table-fn"}
           II                   315     0.8 (0.57−1.13)     0.2
           III                  968     0.74 (0.6−0.9)      0.003[\*](#T1TFN1){ref-type="table-fn"}

\**P*\<0.05.

###### Correlation of *STAT* gene expression level with OS in different clinical stage ovarian cancer patients

  STAT     Clinical stages   Cases   HR (95% CI)        *P*-value
  -------- ----------------- ------- ------------------ ------------------------------------------
  STAT1    I + II            133     2.53 (0.76−8.46)   0.12
           III + IV          1148    0.82 (0.7−0.96)    0.015[\*](#T2TFN1){ref-type="table-fn"}
  STAT2    I + II            81      0.65 (0.22−1.95)   0.44
           III + IV          414     0.97 (0.75−1.25)   0.8
  STAT3    I + II            81      1.1 (0.39--3.17)   0.85
           III + IV          414     0.89 (0.69−1.15)   0.37
  STAT4    I + II            133     0.49 (0.22−1.1)    0.078
           III + IV          1148    0.71 (0.6−0.83)    0[\*](#T2TFN1){ref-type="table-fn"}
  STAT5a   I + II            133     0.33 (0.15−0.73)   0.0038[\*](#T2TFN1){ref-type="table-fn"}
           III + IV          1148    0.75 (0.63−0.9)    0.0014[\*](#T2TFN1){ref-type="table-fn"}
  STAT5b   I + II            133     0.42 (0.17−1)      0.044[\*](#T2TFN1){ref-type="table-fn"}
           III + IV          1148    0.78 (0.67−0.92)   0.0024[\*](#T2TFN1){ref-type="table-fn"}
  STAT6    I + II            133     0.36 (0.16−0.8)    0.0087[\*](#T2TFN1){ref-type="table-fn"}
           III + IV          1148    0.76 (0.63−0.91)   0.0028[\*](#T2TFN1){ref-type="table-fn"}

\**P*\<0.05.

###### Correlation of *STAT* genes expression level with OS in ovarian cancer patients with different TP53 mutation status

  STAT     TP53 mutation   Cases   HR (95% CI)        *P*-value
  -------- --------------- ------- ------------------ ------------------------------------------
  STAT1    No              86      0.67 (0.37−1.24)   0.2
           Yes             439     0.73 (0.56−0.94)   0.013[\*](#T3TFN1){ref-type="table-fn"}
  STAT2    No              11      Not available      Not available
           Yes             57      0.84 (0.48−1.47)   0.53
  STAT3    No              11      Not available      Not available
           Yes             57      0.41 (0.23−0.73)   0.0018[\*](#T3TFN1){ref-type="table-fn"}
  STAT4    No              86      0.61 (0.33−1.12)   0.11
           Yes             439     0.87 (0.68−1.12)   0.28
  STAT5a   No              86      1.82 (0.96−3.46)   0.063
           Yes             439     1.21 (0.92−1.59)   0.16
  STAT5b   No              86      1.75 (0.94−3.24)   0.073
           Yes             439     1.27 (0.98−1.65)   0.065
  STAT6    No              86      1.56 (0.8−3.02)    0.19
           Yes             439     1.45 (1.07−1.97)   0.016[\*](#T3TFN1){ref-type="table-fn"}

\**P*\<0.05.

With regard to clinical stages, while *STAT5a, STAT5b*, and *STAT6* were related to a positive OS both in stages I/II and III/IV ovarian cancer patients, *STAT1* and *STAT4* were correlated to a favorable OS in stages III and IV ovarian cancer patients ([Table 2](#T2){ref-type="table"}).

We further investigated association between individual *STATs* and prognosis according to the TP53 status, *STAT1, STAT3*, and *STAT6* indicated an improved OS in TP53 mutated ovarian cancer patients ([Table 3](#T3){ref-type="table"}).

Discussion {#sec4}
==========

In our present study, we comprehensively investigated the prognostic value of seven *STAT* members in ovarian cancer patients by using the KM plotter database. Amongst the seven genes, only *STAT2* and *STAT3* showed no effect on the OS of ovarian cancers, i.e. high mRNA expression of *STAT1, STAT4, STAT5a, STAT5b*, and *STAT6* was correlated to a better OS for ovarian cancer patients, especially the high level of *STAT1* and *STAT4* was significantly related to a favorable OS for serous ovarian cancer patients.

A number of studies have reported the relationship between STAT1 expression and the prognosis in various types of cancers; however, the results are controversial. Increased STAT1 expression and high STAT1 activation (p-STAT1 protein levels) were related to a favorable prognosis in colorectal carcinoma \[[@B10],[@B11]\], oral squamous cell carcinoma \[[@B12]\], as well as in breast cancer \[[@B13]\]. In addition, Sun et al. \[[@B14]\] observed that overexpression of STAT1 was inversely related to malignant behaviors (lymph node metastasis, tumor dedifferentiation, advanced stage) of pancreatic cancer. And they believed that the silencing of STAT1 expression correlated with poor patient survival and performance \[[@B14]\]. But so far, studies about STAT1 in ovarian cancer are limited. Our results showed that high expression of *STAT1* mRNA was correlated to a better OS for all the ovarian cancer patients, particularly for serous cancer patients. This result is in-line with previous result. In high-grade serous ovarian cancer (HGSC), higher STAT1 expression correlated with increased progression-free survival and predicted better prognosis \[[@B23]\]. In addition, we observed that high mRNA expression of *STAT1* indicated a better OS in grade III and stage III/IV ovarian cancer patients, but not in grade I/II and stage I/II ovarian cancer patients, suggesting that STAT1 is a favorable prognostic marker for ovarian cancer patients, especially for late stage and poor differentiation serous ovarian patients.

STAT2 is unique in the STAT family because it was activated only by interferon \[[@B30]\]. However, little is known about the function of STAT2 in malignancies. In the present study, we found that *STAT2* mRNA levels had no effect on the prognosis of ovarian cancer patients.

STAT3, which can be triggered by cytokines and growth factors \[[@B31],[@B32]\], was constitutively activated in some types of cancer \[[@B10],[@B15],[@B16]\]. It was not only involved in cancer development and progression but also contributed to their survival. STAT3 was overexpressed in colorectal carcinoma and their overexpression contributed to an increase in median OS by approximately 30 months \[[@B10]\]. Grabner et al. \[[@B33]\] detected STAT3 may act as a tumor suppressor through STAT3-NF-κB-IL-8 axis in KRAS mutant lung adenocarcinoma and a molecular marker with favorable prognostic value. In the same line of evidence, it was shown that p-STAT3 was reported as a favorable prognosis marker in breast cancer \[[@B15]\], head and neck squamous cell carcinoma \[[@B16]\], and leiomyosarcoma \[[@B34]\]. Amongst the *STAT* family, *STAT3* is the most studied *STAT* in ovarian cancer. Previous studies have demonstrated that *p-STAT3* was associated with poor survival in ovarian cancer \[[@B24],[@B25]\]. Rosen et al. \[[@B24]\] detected that the activation and translocation of *p-STAT3* to the nucleus were frequent events in ovarian carcinoma, which were associated with a poor prognosis. Yang et al. \[[@B25]\] reported that increased *p-STAT3* expression in omental tissue was associated with poor survival amongst patients with high-grade epithelial ovarian cancer. Intriguingly, our study shows a null association between *STAT3* mRNA expression and OS of ovarian cancer patients. This can be attributed to different study design, detection method (while previous studies measured protein levels, our study was involved in mRNA levels) \[[@B24]\], specimens (Yang et al. \[[@B25]\] using omental tissue), sample size, and cutoff. Therefore, we suggest that the mRNA level of *STAT3* in ovarian tissues shows no effect on OS of ovarian cancers.

STAT4 is one of the STAT family members that specifically mediates IL-12 signaling, affecting a wide range of immune cell physiology \[[@B35]\]. Similar to STAT2, the study about STAT4 in malignancies is limited. Wang et al. \[[@B17]\] demonstrated that STAT4 expression is an independent marker of favorable prognosis and may act as a tumor suppressor in hepatocellularcarcinoma (HCC). To the best of our knowledge, this is the first report investigating the relationship between STAT4 and prognosis of ovarian cancer. In this report, our results show that higher mRNA levels of *STAT4* are significantly correlated to a better OS for all the ovarian cancer patients, especially serous cancer patients. Furthermore, we found that *STAT4* mRNA levels predicted an improved OS in grade III and stage III/IV but not grade I/II and stage I/II ovarian cancer patients, suggesting that this gene is a favorable prognosis indicator especially for late stage and poor differentiation in ovarian cancer patients.

Compared with other STATs, STAT5 consists of two highly homologous isoforms, STAT5a and STAT5b \[[@B4]\]. Although the prognostic role of *STAT5* genes (*STAT5a* and *STAT5b*) varied in different types of cancers, the majority of studies reported that *STAT5* genes predicted a favorable clinical outcome in malignancies. Chen et al. \[[@B18]\] reported that constitutive STAT5 activation was associated with a better survival in cervical carcinoma patients who have accepted radiation therapy. Overexpression of STAT5 in lung cancer was reported to be a positive prognostic marker for patients treated with surgery \[[@B19]\]. Similar results were observed in human breast cancer, i.e. overexpression and overactivation of STAT5 indicated a favorable prognosis of breast cancer \[[@B20]\]. Our current results show that high mRNA expression of *STAT5a* and *STAT5b* related to an improved OS of ovarian cancer, which is consistent with only previous study to explore the impact of STAT5 on the prognosis of ovarian cancer patients \[[@B26]\].

STAT6 has a dual role as signaling molecule and transcription factor \[[@B36]\]. It is tightly connected to IL-4 and IL-13 signaling, and plays a key role in TH2 polarization of the immune system \[[@B36]\]. The study about the prognostic value of STAT6 expression in malignancies is limited. So far, the association between STAT6 and cancer patients' clinical outcomes was only investigated in colorectal cancer. Wang et al. \[[@B37]\] examined 119 colorectal cancer patients by immunohistochemistry and found patients with STAT6-positive expression had lower survival rates than those with STAT6-negative expression. In the present study, we found that high mRNA expression of *STAT6* was correlated to a better OS for all the ovarian cancer patients, suggesting STAT6 has different prognostic significance across cancer types. Furthermore, high mRNA expression of STAT6 was correlated to a better OS in grade III ovarian cancer patients, but not in grade I or II ovarian cancer patients, implying that STAT6 may be a favorable prognostic indictor especially for poor differentiation ovarian cancer.

Interestingly, when we further explored the prognostic roles of individual *STATs* in TP53 mutation, our data shows that *STAT1, STAT3*, and *STAT6*'s high mRNA expression indicated a better OS in TP53 mutated, but not in TP53 wild-type ovarian cancer patients. These observations indicate that STATs family may be favorable prognosis indicators for TP53 mutated ovarian cancer patients. Considering the small sample size of TP53 wild-type ovarian cancer patients, we can not determine the prognostic value of STATs family in these subtype ovarian cancer, further study with large sample size are needed.

Conclusion {#sec5}
==========

In summary, our results show that high mRNA expression of all the individual *STATs* except *STAT2* and *STAT3* are correlated to a better OS for all the ovarian cancer patients, especially the high level of *STAT1* and *STAT4* are significantly related to a favorable OS for serous ovarian cancer patients. And we also found that these genes indicated a favorable prognosis especially for late stage, poor differentiation, and TP53 mutated ovarian cancer patients. These results indicate that STATs family plays a significantly prognostic role in ovarian carcinoma and individual STATs, except STAT2 and STAT3, and may act as a favorable prognostic marker in ovarian cancer. Although our data were statistically significant, the relationship between individual STATs expression and the prognosis of ovarian cancer needs further exploration. Our further studies will validate these results at the in situ protein epression level in human ovarian cancer samples and explore the clinical application of STAT family in ovarian cancer treatment.
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